

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- advanced solid tumor that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy - restricted in strenuous activity but can walk and is able to do light work e.g., light house work, office work - contact study staff for additional requirements

Exclusion Criteria:

- inability to perform the required imaging procedures (e.g., inability to lay flat during scan time) - uncontrolled brain metastasis - history of organ transplantation, including stem cell transplantation - other significant medical or mental health diagnosis (study staff will review)

Conditions & Interventions

Interventions:

Biological: FPI-1175 Infusion, Drug: [111In]-FPI-1547 Injection, Drug: [225Ac]-FPI-1434 Injection multi-dose, Drug: [225Ac]-FPI-1434 Injection single-dose

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Advanced Solid Tumors

More Information

Description: This is an early study of a new drug, called [225Ac]-FPI-1434, to treat solid tumors that have not responded to usual treatment. We are testing different doses of the drug and looking at how well it works for treating the cancer and side effects that occur.

Study Contact: Douglas Yee - yeex006@umn.edu

Principal Investigator: Douglas Yee, MD

Phase: PHASE1

IRB Number: STUDY00013618

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.